Paradigm Biopharmaceuticals has surpassed its Phase 3 enrolment target for Zilosul®, secured over A$21 million in capital, and pivots towards clinical evidence generation with major data readouts expected.
- 538 patients enrolled in global Phase 3 trial, exceeding target
- Raised A$21.74 million via placement and share purchase plan
- Net loss widens to $56.3 million due to trial expenses
- Upcoming interim analysis and primary endpoint readout
- Pipeline expansion and strategic collaborations ongoing
Phase 3 Recruitment Surpasses Expectations
Paradigm Biopharmaceuticals (ASX:PAR) has successfully completed recruitment for its pivotal global Phase 3 trial (PARA_OA_012) of Zilosul®, its injectable pentosan polysulfate sodium therapy for knee osteoarthritis. The company enrolled 538 participants across 57 sites spanning the United States, Australia, Hong Kong, and Moldova, exceeding its original target of 466 patients. This milestone marks a critical transition from operational execution to clinical evidence generation.
The trial’s scale and geographic diversity underscore Paradigm’s operational capabilities, with independent Data Safety Monitoring Board (DSMB) reviews confirming no material safety concerns. The clinical team, led by outgoing Chief Medical Officer Dr Donna Skerrett, praised the high-quality execution and collaboration with partners Advanced Clinical and Nordic Bioscience Clinical Development A/S.
Capital Raised to Support Clinical and Commercial Progress
To underpin the costly Phase 3 program, Paradigm raised approximately A$21.74 million through an institutional placement and a strongly supported Share Purchase Plan (SPP). This was complemented by a staged US$27 million convertible note facility with Obsidian Global Partners, of which US$17 million had been drawn by 30 June 2026, with US$7 million remaining available. The facility’s structure allows drawdowns aligned with operational milestones, reducing upfront capital risk.
The capital injection secured funding for patient follow-up, database management, regulatory preparation, manufacturing readiness, and commercial engagement activities. Attaching listed options exercisable at A$0.2375 per share provide potential for an additional A$28 million if fully exercised, offering a further funding source while incentivising shareholders.
Financial Performance Reflects Investment in Trial Execution
Paradigm reported a net loss after tax of $56.33 million for FY2026, a 200% increase from the prior year’s $18.77 million loss. This widening loss largely reflects a surge in research and development expenses, which rose by over $36 million to $53.9 million, driven by Phase 3 trial costs including patient recruitment, clinical operations, site management, and regulatory activities.
Revenue from continuing operations was modest at $8.13 million, including a small increase in Special Access Scheme sales of iPPS and a $7.62 million R&D tax incentive benefit. General and administrative costs rose moderately, while commercial expenses declined following cost rationalisation efforts. Basic and diluted loss per share widened to 17.91 cents from 5.97 cents, influenced by the higher loss and increased share count from capital raisings.
Next Milestones and Strategic Outlook
With recruitment complete, Paradigm’s immediate focus shifts to the planned Interim Analysis and primary endpoint top-line readout, anticipated in the coming months. These data points represent significant inflection points that could materially influence Paradigm’s valuation and regulatory trajectory.
Beyond the primary data, longer-term follow-up will assess durability of clinical benefit and structural changes via quantitative MRI, building a comprehensive evidence package to support regulatory submissions, physician adoption, and payer engagement. Preparations for a potential New Drug Application (NDA) are underway alongside manufacturing and commercial readiness.
Paradigm is also advancing its pipeline through development of Pentacoxib®, a combination therapy initially targeting veterinary applications, and has established a translational research collaboration with City St George’s, University of London to deepen scientific understanding of pentosan polysulfate’s mechanisms.
Commercially, Paradigm engaged with potential partners at the BIO International Convention, maintaining dialogue on licensing opportunities for Zilosul® across key regions. The company acknowledges the challenging share price environment during its capital raises but emphasizes disciplined execution and funding certainty as priorities.
Governance and Leadership
The company’s board remains stable, with Managing Director Paul Rennie leading the strategic direction. The outgoing Chief Medical Officer Dr Donna Skerrett stepped down to focus on clinical execution, with a successor expected to guide the next phase of evidence generation. The Board dissolved its Remuneration and Nomination Committee, consolidating governance responsibilities to streamline oversight.
Paradigm’s financial statements were audited by RSM Australia Partners, who highlighted the complexity of accounting for the convertible note facility and derivative liabilities, which were fairly valued using market-consistent models. The auditors expressed an unqualified opinion on the financial report.
Bottom Line?
Paradigm’s successful Phase 3 enrolment and secured funding set the stage for pivotal clinical readouts that will test the commercial promise of Zilosul® amid ongoing biotech risks.
Questions in the middle?
- Will the upcoming interim and primary endpoint data validate Zilosul®’s efficacy and safety in osteoarthritis?
- How will Paradigm balance further capital needs with dilution risks as it advances regulatory submissions?
- What impact will strategic partnerships have on Paradigm’s commercialisation timeline and market reach?